• Home
  • Leadership
    • Management Team
    • Advisors
    • Scientific Advisory Board
    • Board of Directors
  • Therapeutic Programs
  • Media
  • Contact
Bootstrapped UNC spinout lands $300K for gene therapy work

Bootstrapped UNC spinout lands $300K for gene therapy work

by Damon Race | Jun 14, 2022 | In the News

The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone – Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In...
Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center

Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center

by Damon Race | Jun 8, 2022 | In the News

Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center

GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center

by Damon Race | Jun 7, 2022 | Press

June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
GeneVentiv Therapeutics Wins KickStart Commercialization Grant

GeneVentiv Therapeutics Wins KickStart Commercialization Grant

by Damon Race | Mar 17, 2022 | In the News

Shar March 16, 2022 By Shellie Edge KickStart Venture Services – the premier life sciences startup program and accelerator from Innovate Carolina – has awarded commercialization grants to two UNC-affiliated startup companies, Elipsys, LLC, and GeneVentiv Therapeutics,...
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect

GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect

by Damon Race | Mar 8, 2022 | In the News

Startup Spotlight: Presenting companies to pitch at CED’s Venture...
« Older Entries
Next Entries »

Recent Posts

  • GeneVentiv targeting gene therapies for hemophilia, Pompe disease
  • Gene therapy developed at Duke to be commercialized by a local biotechnology company
  • GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
  • GeneVentiv Welcomes New Scientific Advisory Board Member, Sylvia Fong
  • GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors

Recent Comments

    Archives

    • May 2025
    • April 2025
    • July 2024
    • April 2024
    • March 2024
    • January 2024
    • November 2023
    • October 2023
    • September 2023
    • August 2023
    • May 2023
    • April 2023
    • February 2023
    • January 2023
    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • November 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020

    Categories

    • In the News
    • Press

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    • Please prove you are human by selecting the Heart.
    • This field is for validation purposes and should be left unchanged.
    • Follow
    Copyright © 2025 GeneVentiv Therapeutics. All rights reserved.
    • Follow